Leukemia Cells and the Cytokine Network: Therapeutic Prospects

Experimental Biology and Medicine

Volumn 229, Issue 2, 2004, Pages 121-137

  Moqattash, Satei ^a   Lutton, John D ^b  

^a SULTAN QABOOS UNIVERSITY   (Oman)

^b NONE

Author keywords

Cytokines; Hematopoiesis; Leukemia; Molecular therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; BRYOSTATIN 1; CALCITRIOL; CALCITRIOL RECEPTOR; CARNOSIC ACID; CD40 LIGAND; CYTOKINE; CYTOKINE RECEPTOR; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FLT3 LIGAND; GENE PRODUCT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; INTERLEUKIN 12; PHORBOL 13 ACETATE 12 MYRISTATE; RECOMBINANT INTERLEUKIN 2; REPRESSOR PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; SCATTER FACTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; APOPTOSIS; BLOOD DISEASE; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; CYTOPENIA; CYTOTOXICITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EFFUSION; GENE EXPRESSION; GENE THERAPY; HEART FAILURE; HEMATOPOIESIS; HOMEOSTASIS; HUMAN; KIDNEY FAILURE; LEUKEMIA CELL; LEUKOCYTOSIS; PHENOTYPE; PROMYELOCYTIC LEUKEMIA; RESPIRATORY DISTRESS; RETINOIC ACID SYNDROME; SHORT SURVEY; SIDE EFFECT; STROMA CELL; WEIGHT GAIN;

EID: 0742287961     PISSN: 15353702     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020422900201     Document Type: Short Survey

References (144)

1. Moqattash S, Lutton JD. Leukemia cells and the cytokine network: a review of the literature. Proc Soc Exp Biol Med 219:8-27, 1998.
2. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 27:1583-1592, 1999.
3. Weekx SF, Van Bockstaele DR, Plum J, Moulijin A, Rodrigus I, Lardon F, De Smedt M, Nijs G, Lenjou M, Loquel P, Berneman ZN, Snoeck HW. CD34+ CD38- and CD34+ CD38+ human hematopoietic progenitors from fetal liver, cord blood, and adult bone marrow respond differently to hematopoietic cytokines depending on the ontogenic source. Exp Hematol 26:1034-1042, 1999.
4. Hareng L, Hartung T. Induction and regulation of endogenous granulocyte colony-stimulating factor formation. Biol Chem 383:1501-1517, 2002.
5. Suzuki M, Harashima A, Okochi A, Yamamoto M, Matsuo Y, Motoda R, Yoshioka T, Orita K. Transforming growth factor-β1 augments granulocyte-macrophage colony-stimulating factor-induced proliferation of umbilical cord blood CD34+ cells with an associated tyrosine phosphorylation of STAT5. Exp Hematol 30:1132-1138, 2002.
6. Kotenko SV. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 13:223-240, 2002.
7. Baetu TM, Hiscott J. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13:199-207, 2002.
8. Sachs L. The control of hematopoiesis and leukemia: from basic biology to the clinic. Proc Natl Acad Sci U S A 93:4742-4749, 1996.
9. + cells. Exp Hematol 30:1238-1247, 2002.
10. Lotem J, Sachs L. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene 13:3284-3294, 2002.
11. Borish LC, Steinke JW. Cytokines and chemokines. J Allergy Clin Immunol 111:S460-S475, 2003.
12. Shen JT, Falanga V. Growth factors, signal transduction, and cellular responses. J Dermatol 30:5-16, 2003.
13. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14:155-174, 2003.
14. Miyamoto M, Prause O, Sjostrand M, Laan M, Lotvall J, Linden A. Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways. Immunol 170:4665-4672, 2003.
15. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 7:1-8, 2002.
16. Maguer-Satta V, Bartholin L, Jeanpierre S, Ffrench M, Martel S, Magaud JP, Rimokh R. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGF-beta family. Exp Cell Res 282:110-120, 2003.
17. Saito M, Kiyokawa N, Tagachi T, Suzuki K, Sekino T, Mimori K, Nakajima H, Katagiri Y, Fujimura J, Fujita H, Ishimato K, Yamashiro Y, Junichiro F. Granulocyte colony-stimulating factor directly affects human monocytes and modulates cytokines secretion. Exp Hematol 30:1115-1123, 2002.
18. Bolwell BJ, Fishleder A, Anderson SW, Lichtin AE, Koo A, Yanssens T, Burwell R, Baucco P, Green R. G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment. Bone Marrow Transplant 12:609-614, 1993.
19. Johnson BS, Mueller L, Si J, Collins SJ. The cytokines IL-3 and GM-CSF regulate the transcriptional activity of retinoic acid in different in vitro models of myeloid differentiation. Blood 99:746-753, 2002.
20. Carstanjen D, Regenfus M, Muller C, Salama A. Interleukin-6 is a major effector molecule of short-term G-CSF treatment inducing bone metabolism and an acute phase response. Exp Hematol 29:812-821, 2001.
21. Okuma E, Inazawa Y, Saeki K, You A. Potential role of extracellular signal-regulated kinase but not p38 during myeloid differentiation of U937 cells stimulated by cytokines: augmentation of differentiation via prolonged activation of extracellular signal-regulated kinase. Exp Hematol 30:571-581, 2002.
22. Shimizu T, Takeda K. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines. Cancer Res 60:4544-4549, 2000.
23. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukemia. Leuk Lymphoma 44:1-7, 2003.
24. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 198:305-313, 2003.
25. Bruserud O, Hovland R, Wergeland L, Huang TS, Gjertsen BT. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 88:416-428, 2003.
26. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines and stromal cells. Exp Hematol 30:973-981, 2002.
27. Reiss M. Transforming growth factor and cancer. Microbes and Infection 15:1327-1347, 1999.
28. Bollag W. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3, and analogues. J Cell Biochem 56:427-435, 1994.
29. Moqattash S, Abraham NG, Lutton JD. Modulation of growth supporting and oncogenic properties of murine leukemia cells. Leuk Res 18:531-539, 1994.
30. Motomura K, Sakai H, Isobe H, Nawata H. Effects of retinoids on the production of tumour necrosis factor-alpha and nitric oxide by lipopolysaccharide-stimulated rat Kupffer cells in vitro: evidence for participation of retinoid X receptor signaling pathway. Cell Biochem Funct 15:95-101, 1997.
31. Takeda K, Akira S. STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11:199-207, 2000.
32. Bollag W. Retinoids and interferon: a new promising combination. Br J Haematol 79:87-91, 1991.
33. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 4(Suppl 3):S233-S242, 2002.
34. Nakashima K, Raga T. gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities. Semin Hematol 35:210-221, 1999.
35. 3 in induction of myeloid differentiation of human leukemic cell lines. J Leukoc Biol 51:237-243, 1992.
36. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood 100:1399-1403, 2002.
37. Drew E, Merkens H, Chelliah S, Doyonnas R, McNagny KM. CD34 is a specific marker of mature murine mast cells. Exp Hematol 30:1211-1218, 2002.
38. Takai K, Hara J, Matsumoto K, Hosoi G, Osugi Y, Tawa A, Okada S, Nakamura T. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood 89:1560-1565, 1997.
39. Fujiki H, Kimura T, Minamiguchi H, Harada S, Wang J, Nakao M, Yokota S, Uruta Y, Ueda Y, Yamagishi H, Sonoda Y. Role of human Interleukin-9 as a megakaryocyte potentiator in culture. Exp Hematol 30:1373-1380, 2002.
40. Gounni AS, Gregory B, Nutku E, Aris F, Latifa K, Minshall E, North J, Tavernier J, Levit R, Nicolaides N, Robinson D, Hamid Q. Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 96:2163-2171, 2000.
41. Sachs L. The cellular and molecular environment in leukemia. Blood Cells 19:709-730, 1993.
42. Lai R, O'Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, Albitar M. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer 95:1071-1075, 2002.
43. Zhou R, Sun G, Wu W. The effect of sera of acute promyelocytic leukemia patients and culture supernatants of NB4 cells on normal granulo-macrophage hematopoiesis. Zhonghua Xue Ye Xue Za Zhi 20:343-346, 1999.
44. Ramshaw HS, Bardy PG, Lee MA, Lopez AF. Chronic myelomonocytic leukemia requires granulocyte-macrophage colony-stimulating factor for growth in vitro and in vivo. Exp Hematol 30:1124-1131, 2002.
45. Zweirzina H, Schollenberger S, Herold M, Schmalzl F, Bezemer J. Endogenous serum levels and surface receptors of GM-CSF and IL-3 in patients with myelodysplastic syndromes. Leuk Res 17:1181-1186, 1992.
46. Manakova TE, Tsvetaeva NV, Levina AA, Momotyuk KS, Sarkisyan GP, Khoroshko ND, Gerasimova LP. In vivo production of cytokines by bone marrow stromal cells and macrophages from patients with myelodysplastic syndrome. Bull Exp Biol Med 132:633-636, 2001.
47. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 77:925-929, 1991.
48. + normal T cells. Br J Hematol 117:59-69, 2002.
49. Aldinucci D, Poletto D, Nanni P, Degan M, Rupolo M, Pinto A, Gattei V. CD40L induces proliferation, self-renewal, rescue from apoptosis and production of cytokines by CD40-expressing AML blasts. Exp Hematol 30:1283-1292, 2002.
50. Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27 (Kip1). Blood 99:2199-2206, 2002.
51. Egyed M, Mihalyfalvi Z, Kollar B, Rumi G, Keller E, Vass J, Fekete S. Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon. Orv Hetil 142:2421-2425, 2001.
52. Stagno F, Guglielmo P, Consoli U, Fiumara P, Longo GS, Giustolisi R. All-trans-retinoic-acid- and growth-factor-mediated induction of alkaline phosphatase activity in freshly isolated chronic myeloid leukemia cells. Acta Haematol 102:61-65, 1999.
53. Liu J, Guo L, Luo Y, Li JW, Li H. All trans-retinoic acid suppresses in vitro growth and downregulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. Anticancer Res 20:2659-2664, 2000.
54. Wu W, Sun G, Wu W, Zhou R, Li X, Shen Z, Wang Z. The relationship between the levels of granulocyte colony-stimulating factor and leukocytosis induced by all-trans retinoic acid in acute promyelocytic leukemia. Chin Med J (Engl) 12:1085-1087, 1999.
55. Ganser A, Seipelt G, Verbeek W, Ottmann OG, Maurer A, Kolbe K, Hess U, Elsner S, Reutzel R, Wormann B, et al. Effect of combination therapy with all trans retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. Leukemia 1994 8:369-375, 1994.
56. Hiroichi N, Satoko M, Keiko B, Yuko T, Ting W, Satoru N, Koichi S. Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice. Pharmacology 58:101-112, 1999.
57. Peck R, Botta W. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines. Eur J Cancer 27:153-157, 1991.
58. Jie C, Tulpule A, Zheng T, Masood R, Espina B, Gill PS. Treatment of epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol 9:433-439, 1997.
59. Federici AB, Stabile F, Castaman G. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 92:2707-2711, 1998.
60. Wightman J, Roberson MS, Lamkin TJ, Varvayanis S, Yen A. Retinoic acid-induced growth arrest and differentiation: retinoic acid up-regulates CD32 (Fc gammaRII) expression, the ectopic expression of which retards the cell cycle. Mol Cancer Ther 1:493-506, 2002.
61. Battle TE, Yen A. Ectopic expression of CXCR5/BLR1 accelerates retinoic acid- and vitamin D(3)-induced monocytic differentiation of U937 cells. Exp Biol Med (Maywood) 227:753-762, 2002.
62. Battle TE, Levine RA, Yen A. Retinoic acid-induced blr1 expression promotes ERK2 activation and cell differentiation in HL-60 cells. Exp Cell Res 254:287-298, 2000.
63. Yen A, Placanica L, Bloom S, Varvayanis S. Polyomavirus small t antigen prevents retinoic acid-induced retinoblastoma protein hypophosphorylation and redirects retinoic acid-induced G0 arrest and differentiation to apoptosis. J Virol 75:5302-5314, 2001.
64. Mannervik M, Nibu Y, Zhang H, Levine M. Transcriptional coregulators in development. Science 284:606-609, 1999.
65. Battle TE, Roberson MS, Zhang T, Varvayanis S, Yen A. Retinoic acid-induced blr1 expression requires RAR-α, RXR, and MAPK activation and uses ERK2 but not JNK/SAPK to accelerate cell differentiation. Eur J Cell Biol 80:59-67, 2001.
66. Bhatia M, Kirkland JB, Meckling-Gill KA. 1,25-Dihydroxyvitamin D3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp Cell Res 222:61-69, 1996.
67. Sharon SY, Williams MA, Newland AC, Colston KW. Leukemia cell differentiation, cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol 32:143-154, 1999.
68. Song X, Norman AW. 1,Alpha,25-dihydroxyvitamin D3 and phorbol ester mediate the expression of alkaline phosphatase in NB4 acute promyelocytic leukemia cells. Leuk Res 22:69-76, 1998.
69. Kaneki M, Inoue S, Hosoi T, Mizuno Y, Akedo Y, Ikegami A, Nakamura T, Shiraki M, Ito H, Suzu S, et al. Effects of 1 alpha, 25-dihydroxyvitamin D3 on macrophage colony-stimulating factor producrion and proliferation of human monocytic cells. Blood 83:2285-2293, 1994.
70. Song XD, Norman AW. Bryostatin-1 and 1,alpha,25-dihydroxyvitamin D3 synergistically stimulate the differentiation of NB4 acute promyelocytic leukemia cells. Leukemia 13:275-281, 1999.
71. Grande A, Montanari M, Tagliafico E, Manfredini R, Marani TZ, Siena M, Tenedini E, Gallinelli A, Ferrari S. Physiological levels of 1,alpha, 25 dihydroxyvitamin D3 induce the monocytic commitment of CD34+ hematopoietic progenitors. Leukoc Biol 71:641-651, 2002.
72. Lotem J, Sachs L. Epigenetics wins over genetics: induction of differentiation in tumor cells. Semin Cancer Biol 12:339-346, 2002.
73. 2 vitamin D3 in induction of erythroid progenitor cell proliferation. Exp Hematol 30:403-409, 2002.
74. Jakubowiak A, Cammenga J, Sokolic R, Alvarez S, Jackson G, Hedvat C, Nimer S. Molecular biology of leukemia. Curr Oncol Rep 2:123-131, 2000.
75. Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 16:559-562, 2002.
76. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14:1777-1784, 2000.
77. Grignani F, De Matteis S, Nervi C. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818, 1998.
78. Wong CW, Privalsky ML. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RAR-alpha, and BCL-6. J Biol Chem 273:27695-27702, 1998.
79. Gelmetti V, Zhang J, Fanelli M. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185-7191, 1998.
80. Fenrick R, Amann JM, Lutterbach B. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 19:6566-6574, 1999.
81. Lutterbach B, Westendorf JJ, Linggi B. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Mol Cell Biol 18:7176-7184, 1998.
82. Fenrick R, Amann JM, Lutterbach B. Both TEL and AML-1 contribute repression domains to the t(12;21) fusion protein. Mol Cell Biol 19:6566-6574, 1999.
83. Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, Boehrer S, Hoelzer D, Ottmann OG, Pelicci PG, Nervi C, Ruthardt M. AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor. Cancer Res 62:7050-7058, 2002.
84. Lin RJ, Nagy L, Inoue S. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814, 1998.
85. Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ. Interaction of CBL with BCR-ABL and CRKL in BCR-ABL transformed myeloid cells. J Biol Chem 272:16170-16175, 1997.
86. Beyermann B, Adams HP, Henze G. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia: a matched-pair analysis. J Clin Oncol 15:2231-2237, 1997.
87. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL. Leukemia 17:691-699, 2003.
88. Badran A, Yoshida A, Wano Y, Imamura S, Kawai Y, Tsutani H, Inuzuka M, Ueda T. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia. Anticancer Res 23:589-592, 2003.
89. Charbord P, Oostendorp R, Pang W, Hérault O, Noel F, Tsuji T, Dzierzak E, Péault B. Comparative study of stromal cell lines derived from embryonic, fetal, and postnatal mouse blood-forming tissue. Exp Hematol 30:1202-1210, 2002.
90. Deryugina EI, Muller-Sieburg CE. Stromal cells in long-term cultures: keys to the elucidation of hematopoietic development. Crit Rev Immunol 13:115-150, 1993.
91. Gidali J, Laszlo E, Halm G, Feher I. Blast colony-forming cell binding from CML bone marrow, or blood, on stromal layers pretreated with G-CSF or SCF. Cell Prolif 35:1-7, 2002.
92. Blazsek I, Delmas Marsalet B, Legras S, Marion S, Machover D, Misset JL. Large scale recovery and characterization of stromal cell-associated primitive haemopoietic progenitor cells from filter-retained human bone marrow. Bone Marrow Transplant 23:647-657, 1999.
93. Blazsek I, Farabos C, Quittet P, Labat ML, Bringuier AF, Triana BK, Machover D, Reynes M, Misset JL. Bone marrow stromal cell defects and 1 alpha,25-dihydroxyvitamin D3 deficiency underlying human myeloid leukemias. Cancer Detect Prev 20:31-34, 1996.
94. Mayani H. Composition and function of the hemopoietic microenvironment in human myeloid leukemia. Leukemia 10:1041-1047, 1996.
95. Flores-Figueroa E, Gutierrez-Espindola G, Montesinos JJ, Arana-Trejo RM, Mayani H. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:677-686, 2002.
96. Afford S, Randhawas S. Apoptosis. Mol Path 53:55-63, 2002.
97. Yuan XM, Li W, Dalen H, Lotem J, Kama R, Sachs L, Brunk UT. Lysosomal destabilization in p53-induced apoptosis. Proc Natl Acad Sci U S A 99:6286-6291, 2002.
98. Lotem J, Sachs L. Cytokines as suppressors of apoptosis. Apoptosis 4:187-196, 1999.
99. Duprey SP, Boettinger D. Developmental regulation of c-myb in normal myeloid progenitor cells. Proc Natl Acad Sci U S A 82:6937-6941, 1985.
100. Fu SL, Lipsick JS. Constitutive expression of full-length c-Myb transforms avian cells characteristic of both the monocytic and granulocytic lineages. Cell Growth Differ 8:35-45, 1997.
101. Wolff L, Schmidt M, Koller R, Haviernik P, Watson R, Bies J, Maciag K. Three genes with different function in transformation are regulated by c-myb in myeloid cells. Blood Cells Mol Dis 27:483-488, 2001.
102. Yi HK, Nam SY, Kim JC, Kim JS, Lee DY, Hwang PH. Induction of apoptosis in K562 cells by dominant negative c-myb. Exp Hematol 30:1139-1146, 2002.
103. Josefsen D, Blomhoff HK, Lomo J, Blystad AK, Smeland EB. Retinoic acid induces apoptosis of human CD34+ hematopoietic progenitor cells: involvement of retinoic acid receptors and retinoid X receptors depends on lineage commitment of the hematopoietic progenitor cells. Exp Hematol 27:642-653, 1999.
104. Ketley NJ, Allen PD, Kelsey SM, Newland AC. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. Blood 90:4578-4587, 1997.
105. Braun S, Gerhartz HH, Schmetzer HM. Lymphokine-activated killer (LAK) cells and cytokines synergize to kill clonal cells in acute myeloid leukemia (AML) in vitro. Haematologia (Budap) 30:271-288, 2000.
106. Braun SW, Gerhartz HH, Schmezzer HM. Influence of cytokines and autologous lymphokine-activated killer cells on leukemic bone marrow cells and colonies in AML. Acta Haematol 105:209-221, 2001.
107. Meloni G, Trisolini SM, Capria S, Torelli GF, Baldacci E, Torromeo C, Valesini G, Mandelli F. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia 16:2016-2018, 2002.
108. Chambaut-Guerin AM, Costa SL, Lefrancois T, Fages C, Gauthereau X, Tardy M. Effects of retinoic acid and tumor necrosis factor alpha on GL-15 glioblastoma cells. Neuroreport 11:389-393, 2000.
109. Xie P, Chan FS, Ip NY, Leung MF. IL-6 enhanced the retinoic acid-induced differentiation of human acute promyelocytic leukemia cells. Cancer Lett 148:207-213, 2000.
110. Shimizu T, Takeda K. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines. Cancer 60:4544-4549, 2000.
111. Visani G, Ottaviani E, Zauli G, Tosi P, Pellacani A, Isidori A, Pierpaoli S, Tura S. All-trans retinoic acid at low concentrations directly stimulates adult megakaryocytopoiesis in the presence of thrombopoietin or combined cytokines. Eur J Haematol 63:149-153, 1999.
112. Grande A, Manfredini R, Tagliafico E, Balestri R, Pizzanelli M, Papa S, Zucchini P, Bonsi L, Bagnara G, Torelli U. All-trans-retinoic acid induces simultaneously granulocytic differentiation and expression of inflammatory cytokines in HL-60 cells. Exp Hematol 23:117-125, 1995.
113. Steiner M, Priel I, Giat J, Levy J, Sharoni Y, Danilenko M. Carnosic acid inhibits proliferation and augments differentiation of human leukemic cells induced by 1,25-dihydroxyvitamin D3 and retinoic acid. Nutr Cancer 41:135-144, 2001.
114. Dore BT, Uskokovic MR, Momparler RL. Mutation in the ligand-binding domain of the retinoic acid receptor alpha in HL-60 leukemic cells resistant to retinoic acid and with increased sensitivity to vitamin D3 analogues. Leuk Res 20:761-769, 1996.
115. Taimi M, Breitman TR. Growth, differentiation, and death of retinoic acid-treated human acute promyelocytic leukemia NB4 cells. Exp Cell Res 10:230:69-75, 1997.
116. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1α,25 dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 1:667-677, 2002.
117. Wightman J, Roberson MS, Lamkin TJ, Varvayanis S, Yen A. Retinoic acid-induced growth arrest and differentiation: retinoic acid up-regulates CD32 (Fc γRII) expression, the ectopic expression of which retards the cell cycle. Mol Cancer Ther 1:493-506, 2002.
118. Coyne DW, Grieff M, Ahya SN, Giles K, Norwood K, Slatopolsky E. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40:1283-1288, 2002.
119. Fenaux P, De Botton S. Retinoic acid syndrome. Recognition, prevention and management. Drug Saf 18:272-279, 1998.
120. Hsu HC, Tsai WH, Chen PG, Hsu ML, Ho CK, Wang SY. In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemia cells. Eur J Hematol 63:11-18, 1999.
121. Shibakura M, Niiya K, Kiguchi T, Shinagawa K, Ishimaru F, Ikeda K, Namba M, Nakata Y, Harada M, Tanimoto M. Simultaneous induction of matrix metalloproteinase-9 and interleukin 8 by all-trans retinoic acid in human PL-21 and NB4 myeloid leukaemia cells. Br J Haematol 118:419-425, 2002.
122. Bertagnolo V, Marchisio M, Pierpaoli S, Colamussi ML, Brugnoli F, Visani G, Zauli G, Capitani S. Selective up-regulation of phospholipase C-β2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors. J Leukoc Biol 71:957-965, 2002.
123. Nimubona S, Grulois I, Bernard M, Drenou B, Godard M, Fauchet R, Lamy T. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases. Leukemia 16:1871-1873, 2002.
124. Egyed M, Mihalyfalvi Z, Kollar B, Rumi G, Keller E, Vass J, Fekete S. Effect of retinoic acid on the cytogenetic remission in the first chronic phase of chronic myeloid leukemia treated with interferon. Orv Hetil 142:2421-2425, 2001.
125. Benthin M, Dallmann I, Atzpodien J. 13-Cis- and all trans-retinoic acid have antiproliferative effects on CML cells and tender IFN-α antiproliferative potency after combined treatment in vitro. Cancer Biother Radiopharm 16:323-331, 2001.
126. Robinson KL, Ayello J, Hughes R, Ven van de C, Issitt L, Kurtzberg J, Cairo MS. Ex vivo expansion maturation and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti CD3, and IL-7: potential for adoptive immunotherapy post-umbilical cord blood transplantation. Exp Hematol 30:245-251, 2002.
127. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 28:1197-1205, 2000.
128. Abu-Ghosh A, Goldman S, Stone V, van de Ven C, Suen Y, Murphy L, Sender L, Cairo M. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-vs-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant 24:535-544, 1999.
129. Thompson JA, Gilliland DG, Prehal JT, Bennell JM, Larholt K, Nelson RA, Rose EH, Dugan MH. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175-1179, 2000.
130. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reillers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004, 2003.
131. Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res 9:1333-1337, 2003.
132. McNamara C, Grigg A, Szer J, Robens A, Campbell L, Hoyt R, Lynch K, Juneja S. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia. Clin Lab Haematol 25:119-125, 2003.
133. Kantarjian H, Talpaz M, O'Brien S, Giles F, Beth Rios M, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97:2225-2228, 2003.
134. Economopoulos T, Fountzilas G, Pavlidis N, Kalantzis D, Papageorgiou E, Christodoulou C, Hamilos G, Nicolaides C, Dimopoulos M. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Hematol J 4:110-115, 2003.
135. Hansen AC, Pedersen FS. Safety features of retroviral vectors. Curr Opin Mol Ther 4:324-333, 2002.
136. Koya RC, Kasahara N, Pullarkat V, Levine AM, Stripecke R. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia 16:1645-1654, 2002.
137. Turturro F. Recombinant adenovirus-mediated cytotoxic gene therapy and lymphoproliferative disorders: analysis based on pharmacodynamics. Curr Drug Targets Immune Endocr Metabol Disord 2:109-118, 2002.
138. Otsu M, Sugamura K, Candotti F. Lack of dominant-negative effects of a truncated γc on retroviral-mediated gene correction of immunodeficient mice. Blood 97:1618-1624, 2001.
139. Khon DB, Sadelain M, Glorioso JC. Occurrence of leukemia following gene therapy of X-linked SCID. Nat Rev Cancer 3:477-488, 2003.
140. Saudemont A, Buffenoir G, Denys A, Desreumaux P, Jouy N, Hetuin D, Bauters F, Fenaux P, Quesnel B. Gene transfer of CD154 and IL-12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. Leukemia 16:1637-1644, 2002.
141. Kipps TJ. Immune and cell therapy of hematologic malignancies. Int J Hematol Suppl 1:269-273, 2002.
142. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21:5716-5724, 2002.
143. Darley RL, Burnell AK. Mutant RAS inhibits neutrophil but not macrophage differentiation and allows continued growth of neutrophil precursors. Exp Hematol 27:1599-1608, 1999.
144. Van Damme A, Vanden Driessche T, Collen D, Chuah MK. Bone marrow stromal cells as targets for gene therapy. Curr Gene Ther 2:195-209, 2002.